Literature DB >> 2181100

Significance of a positive urine group B streptococcal latex agglutination test in neonates.

P J Sánchez1, J D Siegel, N B Cushion, N Threlkeld.   

Abstract

We assessed the clinical significance of a reactive urine latex agglutination (LA) test in neonates without bacteriologically confirmed group B streptococcal (GBS) infection. In a retrospective review of a 3 1/2-month period, during which 367 urine specimens from newborn infants evaluated for suspected sepsis were tested by LA, 25 infants (6.9%) with sterile blood cultures but positive urine LA test results were compared with a control group of 112 infants with both blood cultures and urine LA test results negative for GBS. When the data were studied with stepwise discriminant analysis, the only variables significantly associated with a positive urine LA test result were immature to total neutrophil ratios greater than or equal to 0.16 at 0 and 12 hours. The influence of mucosal GBS colonization on urine LA test results was then investigated prospectively in 98 healthy infants (83 born to mothers colonized with GBS and 15 born to mothers with negative GBS cultures). Eight (8.2%) of the infants studied, or 8 of 52 (15.4%) infants colonized with GBS, had a positive urine LA test result. GBS was isolated from urine cultures of all infants with a positive urine LA test result. A positive urine LA test result was associated with positive GBS rectal and vaginal cultures and with increased density of colonization at those sites. We conclude that contamination of bag specimens of urine with GBS from perineal and rectal colonization may produce a positive urine LA test result in an infant with no systemic sign of infection.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2181100     DOI: 10.1016/s0022-3476(05)81613-0

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  10 in total

1.  False results of latex agglutination tests.

Authors:  M Hacimustafaoglu; N Koksal; M Okan; O Tarim
Journal:  Indian J Pediatr       Date:  2001-01       Impact factor: 1.967

Review 2.  Early diagnosis and treatment of neonatal sepsis.

Authors:  J S Gerdes; R Polin
Journal:  Indian J Pediatr       Date:  1998 Jan-Feb       Impact factor: 1.967

3.  Intrapartum penicillin prophylaxis of early-onset streptococcal infection.

Authors:  A Ohlsson; T L Myhr
Journal:  CMAJ       Date:  1994-04-15       Impact factor: 8.262

Review 4.  Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants.

Authors:  David Kaufman; Karen D Fairchild
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

5.  Sensitivity and specificity of rapid diagnostic tests for detection of group B streptococcal antigen in bacteremic neonates.

Authors:  D N Greenberg; D P Ascher; B A Yoder; D M Hensley; H S Heiman; J F Keith
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

6.  Comparison of commercially available group B streptococcal latex agglutination assays.

Authors:  D P Ascher; S Wilson; G W Fischer
Journal:  J Clin Microbiol       Date:  1991-12       Impact factor: 5.948

7.  Failure of the urinary group B streptococcal antigen test as a screen for neonatal sepsis.

Authors:  M Williamson; S H Fraser; M Tilse
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1995-09       Impact factor: 5.747

8.  Rapid bacterial antigen detection is not clinically useful.

Authors:  M D Perkins; S Mirrett; L B Reller
Journal:  J Clin Microbiol       Date:  1995-06       Impact factor: 5.948

9.  Clinical application of urine antigen detection in early onset group B streptococcal disease.

Authors:  E D McIntosh; H E Jeffery
Journal:  Arch Dis Child       Date:  1992-10       Impact factor: 3.791

Review 10.  Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries.

Authors:  Miwako Kobayashi; Johan Vekemans; Carol J Baker; Adam J Ratner; Kirsty Le Doare; Stephanie J Schrag
Journal:  F1000Res       Date:  2016-09-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.